
Exploring patient characteristics and treatment in real-world endometrial cancer patients users of platinum therapy

Gabriela Abreu, PhD¹; Juliana Queiroz, MSc¹; Thiago Luiz Nogueira da Silva, PhD¹; Claudia Soares, MD, PhD¹; Patricia Menezes, MBA¹; Mariano Carrizo, MD²; Paula Scibona, MD3; Ventura A Simonovich, MD³; María C Riggi, MD³; Florencia Cravero, MD³; Laura Jotimliansky, MD²

¹GSK, Rio de Janeiro, Brazil; ²GSK, Buenos Aires, Argentina; ³Hospital Italiano de Buenos Aires, Buenos Aires, Argentina



Outcomes Study; FIGO, International Federation of Gynecology and Obstetrics; IQR, Interquartile range; PBT, platinum-based therapy; SD, standard deviation.


- 2. Bruggmann D et al. J Transl Med 2020;18:386;

International Society for Pharmacoeconomics and Outcomes (ISPOR) | May 5–8, 2024 | Atlanta, USA

3. Paulino E and de Melo AC. Rev Bras Ginecol Obstet 2023;45:e401–e408.

funded by GSK, in accordance with Good Publication Practice (GPP) guidelines (www.ismpp.org/gpp-2022).

Presenting author: Gabriela Abreu; gabriela.x.abreu@gsk.com



complementary employees of GSK and do not hold stocks or shares. CS, PM, MC, and LJ are employees of and hold stocks in GSK. MCR reports receiving speaker fees from AstraZeneca and GSK. PS, VAS, and FC have no conflicts of interest to declare.



GSK